[1] 姚光弼, 范上达, 廖家杰.临床肝脏病学[M].上海:上海科学技术出版社, 2004∶550-580.
|
[2]Day CP.The potential role of genes in nonalcoholic fatty liver disease[J].Clin Liver Dis, 2004, 8 (3) ∶673-691.
|
[3]Choudhury J, Sanyal AJ.Insulin resistance and the pathogenesis ofnonalcoholic fatty liver disease[J].Clin Liver Dis, 2004, 8 (3) ∶575-594.
|
[4]Bugianesi E, Zannoni C, Vanni E, et al.Non-alcoholic fatty liverand insulin resistance:a cause-effect relationship?[J].Dig LiverDis, 2004, 36 (3) ∶165-173.
|
[5]Videla LA, Rodrigo R, Araya J, et al.Oxidative stress and deple-tion of hepatic long-chain polyunsaturated fatty acids may contributeto nonalcoholic fatty liver disease[J].Free Radic Biol Med, 2004, 37 (9) ∶1499-1507.
|
[6]Yu XH, Zhu JS, Yu HF, et al.Immunomodulatory effect ofoxymatrine on induced CCl4-hepatic fibrosis in rats[J].Chin MedJ, 2004, 117 (12) ∶1856-1858.
|
[7]Tokar JL, Berg CL.Therapeutic Options in Nonalcoholic Fatty LiverDisease[J].Curr Treat Options Gastroenterol, 2002, 5 (6) ∶425-436.
|
[8]Hundal RS, Inzucchi SE.Metformin:newunderstandings, newuses[J].Drugs, 2003, 63 (18) ∶1879-1894.
|
[9]Diehl AM.Tumor necrosis factor and its potential role in insulin re-sistance and nonalcoholic fatty liver disease[J].Clin Liver Dis, 2004, 8 (3) ∶619-638.
|
[10]Lin HZ, Yang SQ, Chuckaree C, et al.Metformin reverses fattyliver disease in obese, leptin-deficient mice[J].Nat Med, 2000, 6 (9) ∶998-1003.
|